PWMG
BMY.RT

Prestige Wealth Management Group’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Prestige Wealth Management Group’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-495
Closed – – 1070
2020
Q4 		$0 Hold
495
– – ﹤0.01% 1073
2020
Q3 		$1K Hold
495
– – ﹤0.01% 869
2020
Q2 		$2K Hold
495
– – ﹤0.01% 723
2020
Q1 		$2K Hold
495
– – ﹤0.01% 701
2019
Q4 		$1K Buy
+495
New +$1.29K ﹤0.01% 565

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Prestige Wealth Management Group's BMY.RT Position: Q1 2021 in Review

Prestige Wealth Management Group sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 495 shares.

Prestige Wealth Management Group first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $2K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Prestige Wealth Management Group reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Prestige Wealth Management Group sold 495 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • Prestige Wealth Management Group first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Prestige Wealth Management Group's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Prestige Wealth Management Group's 13F filing for Q1 2021, filed 13 May 2021.